Summary
The response content provided in the prompt is largely about drug–drug interactions and QT/electrolyte issues, but the evaluation target and FDA label excerpts provided focus specifically on differentiation syndrome warning/management. No claims in the response that align with or discuss differentiation syndrome management steps (e.g., corticosteroids, hemodynamic monitoring, TIBSOVO interruption criteria) are present in the supplied AI-generated statements.
Category Scores
Accurate Statements
Unsupported Statements
Tibsovo absorption and blood levels can drop when stomach acidity is altered.
No supporting label content for acid reducers/absorption or pH-related exposure is provided in the supplied FDA label excerpts (which only address differentiation syndrome).
Drugs that strongly increase stomach pH can reduce Tibsovo exposure.
No supporting label content for proton pump inhibitors/H2 blockers or stomach pH effect is provided in the supplied FDA label excerpts.
Drugs that inhibit liver enzymes or transporters that metabolize or move ivosidenib can raise Tibsovo levels.
No supporting label content for metabolism/transporters or inhibitor/inducer effects is provided in the supplied FDA label excerpts.
Ivosidenib can affect heart electrical activity.
No supporting label content for QT prolongation or ECG monitoring is provided in the supplied FDA label excerpts.
Combining ivosidenib with other QT-prolonging drugs can increase risk.
No supporting label content for QT-prolonging drug interactions is provided in the supplied FDA label excerpts.
Combining ivosidenib with medicines that lower potassium or magnesium can increase risk.
No supporting label content for electrolyte-lowering drug interactions is provided in the supplied FDA label excerpts.
Seek urgent medical advice if symptoms could relate to heart rhythm issues (like fainting, severe dizziness, or palpitations).
No supporting label content for specific urgent symptom guidance related to QT/electrolytes is provided in the supplied FDA label excerpts.
Contradictions
Important Omissions
Differentiation syndrome management guidance referenced in the provided label excerpts (e.g., initiate systemic corticosteroids such as dexamethasone 10 mg IV q12h (or equivalent) and hemodynamic monitoring until improvement and for a minimum of 3 days; interrupt TIBSOVO if severe signs/symptoms persist >48 hours after starting corticosteroids; resume when symptoms improve to Grade 2 or lower).
Importance:
High
The warning content that differentiation syndrome may be life-threatening or fatal and the label-listed symptoms (e.g., noninfectious leukocytosis, edema, dyspnea, hypotension, hypoxia, pulmonary edema, pneumonitis, tumor lysis syndrome, etc.).
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
Because the provided AI statements are not supported by the supplied FDA label excerpts (which cover differentiation syndrome only), they may mislead regarding interaction/QT/electrolyte safety and do not include the label-specific differentiation syndrome warning/management instructions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Mismatch between the evaluation target (differentiation syndrome warning/management) and the AI-provided statements (mostly drug interactions/QT/electrolytes). Additionally, most claims are unsupported by the supplied label excerpts.
Suggested Improvement
Include and precisely reflect the label’s differentiation syndrome warning and management steps from sections 5.1 and 2.3 (corticosteroid initiation/dose, hemodynamic monitoring duration, TIBSOVO interruption timeframe, and resumption criteria). Avoid interaction/QT/electrolyte claims unless the corresponding FDA label sections are provided and cited.